期刊文献+

人顶体酶活性腔性质及与抑制剂的结合模式 被引量:2

Characterization of Human Acrosin Active Site and Binding Modes with Its Inhibitors
下载PDF
导出
摘要 顶体酶是目前抗生育药物的一个潜在靶点.在前期同源模建人顶体酶三维结构复合物的基础上,采用多重拷贝同时搜寻(MCSS)等方法对人顶体酶活性腔进行分析.结果显示,活性腔的P1,P2和G3个区域均具有较大极性,且P1对抑制剂结合尤为重要.另外,G和P1边缘及P2底部还具有一定疏水性,且其中的部分重要残基还能与配体形成氢键作用和静电作用.MCSS计算结果确定的关键配体结合位点与人顶体酶复合物结构和定点突变实验结果相吻合.在此基础上用分子对接方法将6个人顶体酶代表性抑制剂对接入活性腔,阐明其结合模式,确定与配体结合相关的关键残基. Acrosin is a promising target for contraceptive agents. Based on the previous homology modeling of human acrosin, the multiple copy simultaneous search(MCSS) methodology was used to explore the active site of human acrosin. The results show that all of three subsites(P1, P2 and G) are polar zones, and P1 is crucial for inhibitors′ binding. In addition, the edge of P1 and G as well as the bottom of P2 are hydrophobic, in which several important residues form hydrogen-binding interactions and electrostatic interactions. The key residues for ligand binding confirmed by MCSS calculations were consistent with the 3D structure of human acrosin complex and the experiments of site-directed mutagenesis on the animals. On the basis of above results, six of acrosin inhibitors, were docked into the active site of the human acrosin to elucidate their binding mode and the critical residues involved in binding. Our studies provide a basis for the rational design of novel acrosin inhibitors and the discovery of novel contraceptive drugs with high potency.
出处 《高等学校化学学报》 SCIE EI CAS CSCD 北大核心 2009年第12期2409-2414,共6页 Chemical Journal of Chinese Universities
基金 上海市计生委科研基金(批准号:2007JG02) 上海市重点学科建设项目(批准号:B906)资助
关键词 顶体酶 多重拷贝同时搜寻 抑制剂 抗生育药物(KF950) 分子对接 Acrosin Multiple copy simultaneous search Inhibitor Contraceptive drug(KF950) Docking
  • 相关文献

参考文献21

二级参考文献30

共引文献17

同被引文献17

  • 1肖春花,王忠山,左文静,王成忠,许宗革,李亚薇.精子顶体酶活性检测新方法与临床应用[J].男性学杂志,1994,8(4):198-201. 被引量:45
  • 2吕加国,盛春泉,张珉,季海涛,张万年,周有骏,朱驹,蒋俊航.人顶体酶三维结构的同源模建及其与KF950的分子对接研究[J].化学学报,2006,64(10):1073-1078. 被引量:8
  • 3ZHANYing(詹瑛) ZHAOYa-Nan(赵亚南) LIlong-Lin(李宗林) etal.中华男科学,2002,(2):92-94.
  • 4TranterR., ReadJ. A., JonesR., BradyR. L.. Structure[J],2000, 8(11): 1179-1188.
  • 5Breitbart H.. Mol. Cell Endocrinol. [J] 2002, 187(1/2) : 139-144.
  • 6Patrat C., Serres C., Jouannet P.. Biol. Cell[Jl, 2000, 92(3/4) : 255-266.
  • 7Kaminski J. M. , Bauer L. , Mack S. R. , Anderson R. A. , Wailer. D. P. , Zaneveld L.. J. D.. J. Med. Chem. [J] , 1986, 29(4) : 514-519.
  • 8ZHANGXia0一Meng(张晓梦) LUJia-Guo(吕加国).中国新药杂志,2009,18(23):2223-2227.
  • 9TONGLi(仝礼) CHENWen-Hua(陈文华) LIUQiao-Yun(刘巧云) RENZhu-Bing(任诸兵) ZHANGTing(张婷).化学工业与合成,2008,25(6):523-526.
  • 10Cesnek M., Holy A., Masojidkova M., Zidek Z.. Bioorg. Med. Chem. [J], 2005, 13(8) : 2917-2926.

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部